del Romero J, Menendez B, Garcia S, Rodriguez C, Clavo I, Ballesteros J, Arroyo E, Sandoval CS; International Conference on AIDS.

Int Conf AIDS. 1994 Aug 7-12; 10: 155 (abstract no. PB0633).

OBJECTIVE: To ascertain the seroprevalence of anti T.g. antibodies in HIV-seropositive subjects resident in the area of Madrid. POPULATION ANALYSED: Between May 1992 and October 1993, a study was conducted of 1131 HIV-seropositive individuals (881 males and 250 females) who were receiving medical treatment for the HIV infection in an AIDS/STD regional clinic. The average age was 29.6 years (range: 17-70). In accordance with HIV infection risk factors, the patients were grouped as follows: 492 heterosexual Injected Drug Users (IDU) (337 males and 155 females): 495 homo/bisexual non-IDU males and 144 heterosexual non-IDU subjects with other risk factors (49 males and 95 females). METHODS: The 1131 subjects studied, all of whom were HIV-infected (ELISA and Western-blot positive), underwent a cuantitative test to detect anti T.g. IgG antibodies in serum, using an immunoenzyme microparticle technique (MEIA). Results were considered positive at 6 UI/ml. RESULTS: An overall seroprevalence of anti T.g. antibodies of 37.8% was found (39.8% males and 33.6 in females). The following results were observed per age and risk group: TABULAR DATA, SEE ABSTRACT VOLUME. DISCUSSION: The seroprevalence of anti T.g. antibodies found in HIV seropositive individuals is similar to that observed in the general population of our geographical area (X2 = 1.68, 1 d. f., p > 0.05). Likewise, a steady increase of prevalence was observed in the older age groups, these two variables being strongly associated (X2 = 21.43, 3 d. f., p < 0.05). We have observed no significant statistical differences in the prevalence of T.g. infection in relation to the risk group (X2 = 1.29, 2 d. f., p > 0.05). CONCLUSION: In view of its important preventive, diagnostical and clinical implications, testing for anti T.g. antibodies should be performed regularly in the tracking of HIV-infected subjects.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Antibodies, Protozoan
• Bisexuality
• Female
• HIV Infections
• HIV Seropositivity
• Humans
• Male
• Prevalence
• Risk Factors
• Seroepidemiologic Studies
• Spain
• Substance Abuse, Intravenous

Other ID:

• 94371237

UI: 102210067

From Meeting Abstracts